News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Imugene.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Winners: Biotechs up 10pc in November, and Janus Henderson’s prediction for 2024
News
ASX Small Cap Lunch Wrap: It’s a rarity to see so much parity; Cooper’s got new copper
News
Short & Caught: Pilbara Minerals is the ASX’s most shorted as lithium prices tumble
Health & Biotech
Check Up: Imugene’s oncolytic virus VAXINIA granted FDA’s Fast Track, but how effective is this novel therapy?
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Smug ASX ends Tuesday higher, but not much better
News
Top 10 at 10: Special EV loans, M&A, and a big Brazil REE buy
Health & Biotech
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Health & Biotech
ScoPo’s (actually Wilkie’s) Powerplays: Yoga = chill. Fact. And ASX health stocks up for second week
News
ASX Small Caps and IPO Weekly Wrap: Up days, down days = flat week; Medtech multiplies its mojo
Health & Biotech
ASX Health Stocks: AVITA flies as high as 24pc after providing a big, bullish guidance
News
Rise and Shine: Everything you need to know before the ASX opens
News
ASX Small Cap Lunch Wrap: Healthcare stocks lead some frankly marvellous ASX gains on Thursday
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Local markets close lower as RBA bites before Christmas
Health & Biotech
ASX Health Stocks: PYC on the same page with FDA, Cleo’s cancer test peer-reviewed
Health & Biotech
